許繼電氣(000400.SZ):控股股東完成非公開發行5.61億元的可交換債
格隆匯5月18日丨許繼電氣(000400.SZ)公佈,近日,公司收到控股股東許繼集團的通知,許繼集團以其所持公司部分A股股票為標的面向合格機構投資者非公開發行的可交換公司債券已發行完成。債券簡稱為“21許繼EB”,債券代碼為“117186”,實際發行規模為5.61億元,債券期限為2年,初始換股價格15.60元/股,票面利率為0.01%。換股期限自本次可交債發行結束之日起滿六個月後的第一個交易日起至本次可交債到期日前一個交易日止(如為法定節假日或休息日,則順延至下一個交易日)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.